ATE554108T1 - Verfahren bezüglich ldcam und crtam - Google Patents

Verfahren bezüglich ldcam und crtam

Info

Publication number
ATE554108T1
ATE554108T1 AT09011595T AT09011595T ATE554108T1 AT E554108 T1 ATE554108 T1 AT E554108T1 AT 09011595 T AT09011595 T AT 09011595T AT 09011595 T AT09011595 T AT 09011595T AT E554108 T1 ATE554108 T1 AT E554108T1
Authority
AT
Austria
Prior art keywords
ldcam
crtam
procedures regarding
agonists
antagonists
Prior art date
Application number
AT09011595T
Other languages
English (en)
Inventor
Laurent J Galibert
Wei Yan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE554108T1 publication Critical patent/ATE554108T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT09011595T 2003-07-25 2004-07-23 Verfahren bezüglich ldcam und crtam ATE554108T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49002703P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
ATE554108T1 true ATE554108T1 (de) 2012-05-15

Family

ID=34115346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09011595T ATE554108T1 (de) 2003-07-25 2004-07-23 Verfahren bezüglich ldcam und crtam

Country Status (9)

Country Link
US (2) US7267960B2 (de)
EP (2) EP1648935A2 (de)
JP (1) JP2007500132A (de)
AT (1) ATE554108T1 (de)
AU (1) AU2004261941B2 (de)
CA (1) CA2533512C (de)
ES (1) ES2383328T3 (de)
MX (1) MXPA06000974A (de)
WO (1) WO2005012530A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002243A2 (en) 2001-06-27 2003-01-09 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
WO2006090750A1 (ja) 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. 抗IgSF4抗体及びその利用
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
EP2054537A2 (de) 2006-08-02 2009-05-06 Boston Scientific Scimed, Inc. Endoprothese mit dreidimensionaler desintegrationssteuerung
DK2069793T3 (en) * 2006-08-29 2017-04-24 Oxford Biotherapeutics Ltd IDENTIFICATION OF PROTEIN IN CONNECTION WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER
WO2008034031A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
WO2008034047A2 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
ES2357661T3 (es) 2006-09-15 2011-04-28 Boston Scientific Scimed, Inc. Endoprótesis bioerosionables con capas inorgánicas bioestables.
ATE517590T1 (de) 2006-09-15 2011-08-15 Boston Scient Ltd Biologisch erodierbare endoprothesen
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
JP2010503482A (ja) 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド 内部人工器官
JP5355418B2 (ja) 2006-12-28 2013-11-27 ボストン サイエンティフィック リミテッド 生侵食性内部人工器官、及び該生侵食性内部人工器官を製造する方法
US20100247430A1 (en) * 2007-08-30 2010-09-30 Andrew Chan Methods and Compositions for Modulating T Cells
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
WO2009097017A2 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
EP2403546A2 (de) 2009-03-02 2012-01-11 Boston Scientific Scimed, Inc. Selbstpufferende medizinische implantate
ME02842B (de) 2009-03-05 2018-01-20 Squibb & Sons Llc Cadm1-spezifische vollständig humane antikörper
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
ES2690199T3 (es) * 2009-07-21 2018-11-19 Abt Holding Company Uso de células madre para reducir la extravasación de leucocitos
WO2011119573A1 (en) 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
MX378790B (es) * 2014-07-21 2025-03-10 Delinia Inc Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
WO2016154341A1 (en) * 2015-03-23 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of crtam agonists
US11083868B2 (en) * 2015-05-13 2021-08-10 Innoventions Ltd. System for inhibiting biofilm formation on catheters, other indwelling or implantable devices and other devices
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CA3079313A1 (en) * 2017-11-02 2019-05-09 Oxford Biotherapeutics Ltd Antibodies and methods of use
CN108333132A (zh) * 2018-02-22 2018-07-27 哈尔滨工业大学 一种煤化工废水的生物毒性检测方法
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
JP2023545852A (ja) * 2020-10-20 2023-10-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 養子細胞療法のための注射可能なヒドロゲル
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
TW202317631A (zh) * 2021-06-30 2023-05-01 大陸商南京聖和藥業股份有限公司 抗crtam抗體及其應用
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0276846A3 (de) 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0557300B1 (de) 1990-10-29 1997-11-19 Chiron Corporation Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
EP0669929B1 (de) 1992-11-13 2007-01-03 Immunex Corporation Elk ligand, ein cytokin
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2169191C (en) 1993-08-26 2008-01-15 Elizabeth A. Wang Neural regeneration using human bone morphogenetic proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
EP0766564A4 (de) 1994-06-24 1998-09-23 Immunex Corp Kontrollierte freisetzung von polypeptidzusammensetzungen und methoden der behandlung von entzündlichen erkrankungen der eingeweide
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5877155A (en) 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5686257A (en) * 1995-04-26 1997-11-11 Schering Corporation Binding compositions for mammalian T cell antigens and related reagents
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
JP2001513987A (ja) 1997-08-22 2001-09-11 ワシントン大学 誘導性制御システムおよびその使用
NZ504548A (en) 1997-12-03 2003-06-30 Genentech Inc Polypeptides and nucleic acids encoding human chordin
US20020165143A1 (en) 1997-12-03 2002-11-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999057132A1 (en) 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
DE69942861D1 (de) * 1998-08-07 2010-11-25 Immunex Corp Ldcam genannte moleküle
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2348824A1 (en) 1998-10-28 2000-05-25 Human Genome Sciences, Inc. 12 human secreted proteins
MXPA01005425A (es) 1998-12-01 2002-04-24 Genentech Inc Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2172800A (en) 1998-12-10 2000-06-26 Washington University Protein transduction system and methods of use thereof
CA2339404A1 (en) 1999-06-30 2001-01-04 Sigma-Aldrich Co. Synthetic peptide immunogens and antibodies thereto
AU2001286514A1 (en) * 2000-08-15 2002-02-25 National Cancer Center Research Institute Diagnosis and treatment of tumor-suppressor associated disorders
WO2002026930A2 (en) 2000-09-26 2002-04-04 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
NL2002787C2 (en) 2009-04-23 2010-10-26 Medspray Xmems Bv Atomising body, atomising device, inhaler, manufacturing method of manufacturing an atomising body and assembly method for assembling an atomising device.

Also Published As

Publication number Publication date
JP2007500132A (ja) 2007-01-11
US7267960B2 (en) 2007-09-11
WO2005012530A3 (en) 2005-05-12
ES2383328T3 (es) 2012-06-20
US20080064104A1 (en) 2008-03-13
US8043615B2 (en) 2011-10-25
EP2133362B1 (de) 2012-04-18
CA2533512A1 (en) 2005-02-10
AU2004261941A1 (en) 2005-02-10
CA2533512C (en) 2013-06-11
US20050058642A1 (en) 2005-03-17
AU2004261941B2 (en) 2008-04-10
MXPA06000974A (es) 2006-08-31
EP1648935A2 (de) 2006-04-26
WO2005012530A2 (en) 2005-02-10
EP2133362A1 (de) 2009-12-16

Similar Documents

Publication Publication Date Title
ATE554108T1 (de) Verfahren bezüglich ldcam und crtam
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
SE0302304D0 (sv) Novel compounds
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний